Loading
A phase 2 trial of JNJ-90301900, Durvalumab and Carboplatin in non-small-cell lung cancer, run by Johnson & Johnson Enterprise Innovation Inc., now recruiting.
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06667908 by Johnson & Johnson Enterprise Innovation Inc., with 130 participants planned, started 2024-12-06 and due to reach its primary completion in 2028-12-31. Interventions recorded: JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin and Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Unresectable stage III non-small-cell lung cancer, Carboplatin, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, Carboplatin, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, Carboplatin, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Unresectable stage III non-small-cell lung cancer, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, Carboplatin, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.